<DOC>
	<DOC>NCT00458016</DOC>
	<brief_summary>The purpose of this study is to collect important information regarding the safety, tolerability, and efficacy of MB07803 when administered for 28 days in patients with type 2 diabetes mellitus</brief_summary>
	<brief_title>Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Fasting plasma glucose between 120 270 mg/dL at screening HbA1c measurements between 6.0 10% at screening Females who are surgically sterile (i.e. women who have had a hysterectomy or tubal ligation). Females who are postmenopausal for at least 12 consecutive months and documented by blood follicular stimulating hormone (FSH) greater than or equal to 40 mlU/mL.Females of childbearing potential must be willing to use an approved doublebarrier method of birth control (e.g. condom plus spermicide ;IUD plus spermicide) from the time of signing the informed consent form through 4 weeks following the last dose of study drug. Body mass index (BMI) in the range of 18.5 37 kg/m2 Patients with a BMI in the range of 37.5 40 kg/m2 who in the Investigator's opinion, are in good health and satisfy the eligibility criteria, will be considered on a caseby case basis Written informed consent Type 1 diabetes mellitus Type 2 diabetes mellitus with a history of diabetic ketoacidosis or ketosisprone Use of thiazolidinediones (TZDs) Currently on more than two oral hypoglycemic agent History of outpatient insulin use Clinically significant history of cardiac disease within 6 months of informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>